Letters and drug alerts sent to healthcare professionals in August 2019

A letter was sent to advise healthcare professionals about a restriction to the indication and route of administration for Mitomycin-C Kyowa 40 mg following the observation of increased sub-visible particles in the drug product on storage. A letter was also sent to notify healthcare professionals of a risk of medication error with various Santen eye drop products during the period of transition to new bottles.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 19 September 2019

• Therapeutic area: Cancer, Ophthalmology, Urology and nephrology

Letters

The following letters were sent to healthcare professionals in August 2019:

• Mitomycin-C Kyowa 40 mg: restricted to intravesical administration only for treatment of superficial bladder cancer

• Santen eye drop products (Cosopt, Trusopt, Timoptol): risk of medication error in transition to new bottles

Article citation: Drug Safety Update volume 13, issue 2: September 2019: 5.

Published 19 September 2019